Comparison of outcomes after 123I versus 131I preablation imaging before radioiodine ablation in differentiated thyroid carcinoma

Journal of Nuclear Medicine

Volumn 48, Issue 7, 2007, Pages 1043-1046

  Silberstein, Edward B ^a  

^a UNIVERSITY OF CINCINNATI MEDICAL CENTER   (United States)

Author keywords

123I iodine; 131I iodine; Ablation; Stunning; Thyroid carcinoma

Indexed keywords

IODINE 123; IODINE 131; THYROGLOBULIN; THYROTROPIN;

ADULT; ARTICLE; CANCER STAGING; CELL DAMAGE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; HUMAN; ISOTOPE LABELING; MALE; MINIMAL RESIDUAL DISEASE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; THYROGLOBULIN BLOOD LEVEL; THYROID CARCINOMA; THYROID FOLLICULAR CARCINOMA; THYROID PAPILLARY CARCINOMA; THYROIDECTOMY; THYROTROPIN BLOOD LEVEL; TUMOR VOLUME;

ADENOCARCINOMA, FOLLICULAR; ADULT; CARCINOMA, PAPILLARY; FEMALE; HUMANS; IODINE RADIOISOTOPES; MALE; MIDDLE AGED; RADIOPHARMACEUTICALS; THYROID HORMONES; THYROID NEOPLASMS; THYROIDECTOMY; TREATMENT OUTCOME;

EID: 34447317801     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: 10.2967/jnumed.107.040311     Document Type: Article

References (22)

1. Thomas SR. Options for radionuclide therapy: from fixed activity to patient-specific treatment planning. Cancer Biother Radiopharm. 2002;17:71-82.
2. Maxon HR, Englaro EE, Thomas SR, et al. Radioiodine-131 therapy for well-differentiated thyroid cancer: quantitative radiation dosimetric approach - outcome and validation. J Nucl Med. 1992;33:1132-1136.
3. 131I. Nucl Med Commun. 1996;17:839-842.
4. 131I diagnostic whole-body scanning [abstract]. J Nucl Med. 2001;42(suppl):986P-987P.
5. Rawson RW, Rall JE, Peacock W. Limitations in the treatment of cancer of the thyroid with radioactive iodine. J Clin Endocrinol. 1951;11:1128-1142.
6. Brenner W. Is stunning a real phenomenon or just fiction? J Nucl Med. 2002;43:835-836.
7. Intenzo CM, Jabbour S, Dam HQ. et al. Changing concepts in the management of differentiated thyroid cancer. Semin Nucl Med. 2005;35:257-265.
8. Yaakob W, Gordon L, Spicer KM, et al. The usefulness of iodine-123 wholebody scans in evaluating thyroid carcinoma and metastases. J Nucl Med Technol. 1999;27:279-281.
9. Mandel SJ, Shankar LK, Benard F, et al. Superiority of iodine-123 compared with iodine-131 scanning for thyroid remnants in patients with differentiated thyroid cancer. Clin Nucl Med. 2001;26:6-9.
10. 123I for imaging to assess the need for therapy. Nucl Med Commun. 2006;27:165-169.
11. Park H-M, Park Y-H, Zhou X-H. Detection of thyroid remnant/metastases without stunning: an ongoing dilemma. Thyroid. 1997;7:277-279.
12. Leger FA, Izembart M, Dagousset F, et al. Decreased uptake of therapeutic doses of iodine-131 after 185 MBq iodine-131 diagnostic imaging for thyroid remnants in differentiated thyroid carcinoma. Eur J Nucl Med. 1998;25:242-246.
13. Dam HQ, Kim SK, Lin HC, et al. I-131 therapeutic efficacy is not influenced by stunning after diagnostic whole-body scanning. Radiology. 2004;232:527-533.
14. Karam M, Giannoukakis A, Feustel PJ, et al. Influence of diagnostic and therapeutic doses on thyroid remnant ablation rates. Nucl Med Commun. 2003;24:489-495.
15. 131I-scanned and nonscanned individuals. J Clin Endocrinol Metab. 2001;86:3507-3511.
16. Muratet J-P, Daver A, Minier J-F, et al. Influence of scanning dose of iodine-131 on subsequent first ablative treatment outcome in patients operated on for differentiated thyroid carcinoma. J Nucl Med. 1998;39:1546-1550.
17. 131I. Eur J Nucl Med. 2002;29:1421-1427.
18. 131I on postsurgical thyroid remnants. J Nucl Med. 2000;41:2038-2042.
19. 123I. Eur J Nucl Med. 2002;29:783-788.
20. Heo Y-J, Song H-C, Min J-J, et al. Thyroid stunning induced by I-123 scan in postoperative patients with papillary thyroid cancer: comparison with I-131 scan [abstract]. J Nucl Med. 2005;46(suppl):310P.
21. Humm JL, Charlton D. A new calculational method to assess the therapeutic potential of Auger electron emissions. Int J Radiat Oncol Biol Phys. 1989;17:351-360.
22. Haugen BR, Pacini F, Reiners C, et al. A comparison of recombinant human thyrotropin and thyroid hormone withdrawal for the detection of thyroid remnant or cancer. J Clin Endocrinol Metab. 1999;84:3877-3885.